Elekta Valuation

Is EKTA.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKTA.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$10.08
Fair Value
45.8% undervalued intrinsic discount
13
Number of Analysts

Below Fair Value: EKTA.F ($5.46) is trading below our estimate of fair value ($10.08)

Significantly Below Fair Value: EKTA.F is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKTA.F?

Key metric: As EKTA.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EKTA.F. This is calculated by dividing EKTA.F's market cap by their current earnings.
What is EKTA.F's PE Ratio?
PE Ratio23.4x
EarningsSEK 1.00b
Market CapSEK 23.48b

Price to Earnings Ratio vs Peers

How does EKTA.F's PE Ratio compare to its peers?

The above table shows the PE ratio for EKTA.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.8x
CNMD CONMED
16.1x13.8%US$2.1b
LMAT LeMaitre Vascular
51.6x12.2%US$2.1b
NUVA NuVasive
73.3x46.2%US$2.1b
LIVN LivaNova
110.2x48.2%US$2.6b
EKTA.F Elekta
23.4x21.3%US$23.5b

Price-To-Earnings vs Peers: EKTA.F is good value based on its Price-To-Earnings Ratio (23.4x) compared to the peer average (59.3x).


Price to Earnings Ratio vs Industry

How does EKTA.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$9.15m
PAVM PAVmed
0.5x-90.0%US$7.02m
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
EKTA.F 23.4xIndustry Avg. 34.8xNo. of Companies7PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EKTA.F is good value based on its Price-To-Earnings Ratio (23.4x) compared to the US Medical Equipment industry average (34.8x).


Price to Earnings Ratio vs Fair Ratio

What is EKTA.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKTA.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EKTA.F's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKTA.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.46
US$6.60
+20.9%
27.7%US$11.49US$4.66n/a13
Jan ’26n/a
US$6.66
0%
27.1%US$11.52US$4.67n/a13
Dec ’25US$5.90
US$6.81
+15.4%
26.0%US$11.66US$5.23n/a13
Nov ’25n/a
US$7.10
0%
23.6%US$11.82US$5.30n/a14
Oct ’25n/a
US$7.41
0%
23.8%US$12.34US$5.54n/a14
Sep ’25US$6.70
US$7.52
+12.2%
24.7%US$12.45US$5.59n/a13
Aug ’25n/a
US$7.05
0%
24.9%US$11.74US$5.27n/a13
Jul ’25US$6.25
US$7.29
+16.7%
24.7%US$12.13US$5.44n/a13
Jun ’25n/a
US$7.88
0%
24.4%US$11.90US$5.34n/a12
May ’25n/a
US$7.78
0%
24.5%US$11.84US$5.31n/a12
Apr ’25n/a
US$8.41
0%
23.7%US$12.42US$5.58n/a12
Mar ’25US$7.22
US$8.37
+15.9%
23.4%US$12.31US$5.52n/a12
Feb ’25US$7.48
US$8.30
+11.0%
23.4%US$12.16US$5.46n/a12
Jan ’25US$8.15
US$8.08
-0.9%
23.3%US$12.10US$5.43n/a11
Dec ’24n/a
US$8.18
0%
23.7%US$12.24US$5.49US$5.9011
Nov ’24n/a
US$7.47
0%
26.2%US$11.57US$4.83n/a11
Oct ’24US$6.82
US$7.58
+11.1%
26.6%US$11.55US$4.82n/a10
Sep ’24US$7.02
US$7.58
+7.9%
26.6%US$11.55US$4.82US$6.7010
Aug ’24US$8.22
US$8.02
-2.5%
26.2%US$12.24US$5.49n/a10
Jul ’24n/a
US$7.97
0%
26.0%US$11.84US$5.32US$6.2510
Jun ’24n/a
US$7.68
0%
25.5%US$11.70US$5.25n/a10
May ’24US$8.34
US$7.84
-6.0%
28.3%US$12.25US$5.50n/a10
Apr ’24US$7.45
US$7.84
+5.2%
28.3%US$12.25US$5.50n/a10
Mar ’24US$7.63
US$7.50
-1.8%
28.7%US$12.22US$5.48US$7.229
Feb ’24US$7.27
US$7.04
-3.1%
31.5%US$12.14US$4.97US$7.489
Jan ’24US$6.06
US$6.81
+12.5%
31.8%US$12.28US$5.03US$8.159
Analyst Price Target
Consensus Narrative from 13 Analysts
US$6.48
Fair Value
15.7% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 22:27
End of Day Share Price 2025/01/03 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Elekta AB (publ) is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumit SayalAlphaValue
Alexander KlebanBarclays
Hassan Al-WakeelBarclays